⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28066082 | 0.78 | — | — | |
| SCHEMBL16636031 | 0.74 | — | — | |
| SCHEMBL25309239 | 0.70 | — | — | |
| SCHEMBL25309241 | 0.70 | — | — | |
| SCHEMBL9143364 | 0.69 | — | — | |
| SCHEMBL26116030 | 0.69 | — | — | |
| SCHEMBL8738683 | 0.67 | — | — | |
| SCHEMBL25299741 | 0.66 | — | — | |
| SCHEMBL17621627 | 0.65 | — | — | |
| SCHEMBL13455883 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024017178-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | AVITAR BIOSCIENCES, INC. (CN) | 2024-01-25 | — | — | WO | disclosed |
| CN-112236415-B | Process for the preparation of aminopyrimidines and intermediates therefor | 赛特凯恩蒂克公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151636-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-112236415-A | Process for preparing aminopyrimidines and intermediates thereof | 赛特凯恩蒂克公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3732166-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | Cytokinetics, Incorporated (US) | 2020-11-04 | — | — | EP | disclosed |